Gonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE Groups 3-4): a multicenter randomized controlled trial.
文献摘要
Introduction Idiopathic non-obstructive azoospermia (NOA) is a severe form of male infertility with limited non-surgical treatment options. Microdissection testicular sperm extraction (micro-TESE) remains the standard approach for sperm retrieval, yet success rates vary substantially, and many patients undergo surgery without successful sperm recovery. Hormonal optimization using human chorionic gonadotropin (hCG) with or without follicle-stimulating hormone (FSH) has been proposed to improve spermatogenesis in hypogonadal men, but evidence from randomized controlled trials is lacking. This multicenter trial evaluates whether gonadotropin-based hormonal optimization improves sperm availability for intracytoplasmic sperm injection (ICSI) compared with standard-of-care (SOC) management in men with idiopathic NOA and biochemical hypogonadism. Methods and analysis This multicenter, randomized, controlled, parallel-group superiority trial will allocate participants 1:1 to hormonal therapy or SOC. Eligible participants are men with idiopathic NOA, total testosterone Ethics and dissemination The study was approved by Institution Ethics Committee (IIVF-UA00l 00). Clinical trial registration (https://clinicaltrials.gov/study/NCT07540611), identifier NCT07540611.